Regorafenib versus TAS-102 as Salvage-line in patients with colorectal cancer refractory to standard chemotherapies: a multicenter observational study
收藏NIAID Data Ecosystem2026-03-09 收录
官方服务：
资源简介：
Primary outcome(s): Overall survival
创建时间：
2016-01-15
